stockrow
Friday 6 November 2026
Export BLCO’s income statement to Excel — free account
Bausch + Lomb Corporation
BLCO Healthcare Medical Instruments & Supplies
Bausch + Lomb Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 6.47% from fiscal 2024.
- Revenue
- +7.34%
- EPS
- +222.4%
- Free cash flow
- +182.5%
- Total debt
- +2.93%
Quarter to September 2026, against a year earlier
19.94
0.66
−3.20%
Follow BLCO
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 5 | 5 | 6 |
| (5.51%) | (3.40%) | (2.64%) | (1.71%) | ||
| (2.62%) | (1.61%) | (1.24%) | (0.80%) | ||
ROIC |
0.63% | 1.27% | 1.81% | 2.16% | |
Return on Tangible Assets |
(12.77%) | (7.96%) | (6.04%) | (3.82%) | |
Average Days of Receivables |
87.37 | 77.51 | 79.53 | 77.27 | |
Free Cash Flow per Share |
(0.19) | 0.00 | 0.38 | 0.70 | |
Free Cash Flow |
(66.00) | 1.00 | 137.00 | 252.00 | |
Capital Expenditures |
(349.00) | (339.00) | (321.00) | (302.00) | |
| Other line items | |||||
Cash ROIC |
(0.55%) | 0.01% | 1.15% | 2.08% | |
Accounts Receivable Turnover |
4.54 | 4.93 | 4.75 | 4.85 | |
Accounts Payable Turnover |
5.28 | 4.92 | 4.69 | 5.33 | |
Inventory Turnover |
2.04 | 2.04 | 2.00 | 2.02 | |
Average Days of Payables |
69.08 | 72.43 | 75.74 | 66.02 | |
Days of Inventory on Hand |
173.78 | 173.87 | 177.61 | 181.15 | |
Tax Rate |
0.11 | 0.05 | 1.51 | 24.75 | |
Research and Development Expense of Revenue |
7.27% | 7.41% | 7.59% | 7.38% | |
Selling, General and Administrative Expense of Revenue |
43.80% | 42.53% | 41.77% | 41.57% | |
Share Based Compensation of Revenue |
2.92% | 2.98% | 3.06% | 3.19% | |
Interest Coverage |
0.27 | 0.54 | 0.83 | 1.00 | |
Operating CF/Net income |
(0.79) | (1.55) | (2.68) | (4.99) | |
Depreciation/Fixed assets |
0.25 | 0.24 | 0.24 | 0.23 | |
Capex/Depreciation |
(0.79) | (0.78) | (0.75) | (0.72) | |
Revenue per Share |
14.42 | 14.66 | 14.91 | 15.15 | |
Operating CF per Share |
0.80 | 0.96 | 1.28 | 1.55 | |
Capex per Share |
(0.99) | (0.95) | (0.90) | (0.84) | |
Capex to Sales |
0.07 | 0.07 | 0.06 | 0.06 |
Columns are period end dates · fundamentals updated 2 Nov 2026